diabetes glp-1 agonist How Receptor Agonists Evolved from to Weight Loss Treatments GLP-1-based therapies for type 2

The company that wins here could set the tone for pharmas next decade, and investors know it

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

(I am a big advocate of spacing out doses for people who have reached their goal weight, OR who are taking GLP-1s primarily for a possible metabolic/anti-inflammatory benefit, and who want to keep their weight neutral.) But maintenance dosing after achieving a clinical response is a completely different concept from starting at a sub-therapeutic dose and hoping it works

7 This preclinical work has now been translated to a population of patients with raised ICP due to IIH

NASH occurs when fat deposits cause the liver to become swollen and damaged

A 12 months longitudinal study